Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...

NEW YORK CITY, NY / ACCESS Newswire / January 20, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Novo ...

Novo is currently in a golden age of growth. Over the last five years, its trailing-12-month revenue grew by 109%, reaching ...

Weight-loss and diabetes drugs reduced the risk of developing Alzheimer’s, an independent study published Monday showed.

Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for ...

The Biden administration said Medicare will negotiate discounts with drug companies on 15 drugs prescribed to treat cancer, ...

Novo Nordisk said a higher dose of its drug Wegovy led to greater weight loss in patients during a late-stage trial, but the ...

Denmark's Prime Minister Mette Frederiksen had summoned business leaders after speaking on Wednesday with U.S.

Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight ...

USA vil forhandle pris på Wegovy og Ozempic med Novo Nordisk Wegovy og Ozempic er udvalgt til prisforhandlinger i USA. Novo har seks uger til at vælge, om man vil deltage. Novo-midlerne Wegovy og ...

Tirsdag sagde Novo Nordisk, at flere af dets insulinprodukter i USA bliver billigere. Nu sænker Sanofi prisen. Novo Nordisk-konkurrenten Sanofi sænker listepriserne på insulin i USA med op til 78 ...

It hasn't been a great period for investors in Novo Nordisk (NYSE: NVO) despite its ongoing status as one of the pharmaceutical industry's apex competitors in the field of cardiometabolic drugs.